Vandetanib for the second line treatment of non-small cell lung cancer [ID46]
Discontinued
Reference number: GID-TAG405
Following on from information provided to NICE by the company in November 2009, the appraisal of Vandetanib for the second line treatment of non-small cell lung cancer [ID46] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.